Literature DB >> 21211688

Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators.

Massimo Santini1, Maurizio Gasparini, Maurizio Landolina, Maurizio Lunati, Alessandro Proclemer, Luigi Padeletti, Domenico Catanzariti, Giulio Molon, Giovanni Luca Botto, Laura La Rocca, Andrea Grammatico, Giuseppe Boriani.   

Abstract

OBJECTIVES: The purpose of this analysis was to evaluate the correlation between atrial tachycardia (AT) or atrial fibrillation (AF) and clinical outcomes in heart failure (HF) patients implanted with a cardiac resynchronization therapy defibrillator (CRT-D).
BACKGROUND: In HF patients, AT and AF have high prevalence and are associated with compromised hemodynamic function.
METHODS: Forty-four Italian cardiological centers followed up 1,193 patients who received a CRT-D according to current guidelines for advanced HF, New York Heart Association functional class ≥ II, left ventricular ejection fraction ≤ 35%, and QRS complex ≥ 120 ms. All patients were in sinus rhythm at implant.
RESULTS: During a median follow-up period of 13 months, AT/AF >10 min occurred in 361 of 1,193 (30%) patients. The composite end point (deaths or HF hospitalizations) occurred in 174 of 1,193 (14.6%). Multivariate time-dependent Cox regression analyses showed that composite end point risk was higher among patients with device-detected AT/AF (hazard ratio [HR]: 2.16, p = 0.032), New York Heart Association functional class III or IV compared with II (HR: 2.09, p = 0.002), and absence of beta-blockers (HR: 1.36, p = 0.036). Furthermore, the composite end point risk was inversely associated with left ventricular ejection fraction (HR: 1.04, p = 0.045), increasing by a factor of 4% for each 1% decrease in left ventricular ejection fraction.
CONCLUSIONS: In HF patients with CRT-D, device-detected AT/AF is associated with a worse prognosis. Continuous device diagnostics monitoring and Web-based alerts may inform the physician of AT/AF occurrences and identify patients at risk of cardiac deterioration or patients with suboptimal rate or rhythm control. (Italian ClinicalService Project; NCT01007474).
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21211688     DOI: 10.1016/j.jacc.2010.08.624

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

1.  Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study.

Authors:  Alan S Go; Kristi Reynolds; Jingrong Yang; Nigel Gupta; Judith Lenane; Sue Hee Sung; Teresa N Harrison; Taylor I Liu; Matthew D Solomon
Journal:  JAMA Cardiol       Date:  2018-07-01       Impact factor: 14.676

2.  Use of novel oral anticoagulants in patients with heart failure.

Authors:  Eduard Shantsila; Gregory Y H Lip
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

4.  A prospective comparison of remote monitoring systems in implantable cardiac defibrillators: potential effects of frequency of transmissions.

Authors:  Ermenegildo de Ruvo; Luigi Sciarra; Anna Maria Martino; Marco Rebecchi; Renzo Venanzio Iulianella; Francesco Sebastiani; Alessandro Fagagnini; Alessio Borrelli; Antonio Scarà; Domenico Grieco; Claudia Tota; Federica Stirpe; Leonardo Calò
Journal:  J Interv Card Electrophysiol       Date:  2016-01       Impact factor: 1.900

Review 5.  Rate Control in Atrial Fibrillation: Methods for Assessment, Targets for Ventricular Rate during AF, and Clinical Relevance for Device Therapy.

Authors:  Shantanu Sarkar; Paul D Ziegler
Journal:  J Atr Fibrillation       Date:  2013-06-30

Review 6.  Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure.

Authors:  Felix Hohendanner; F R Heinzel; F Blaschke; B M Pieske; W Haverkamp; H L Boldt; A S Parwani
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

7.  Subclinical atrial fibrillation frequency and associated parameters in patients with cardiac resynchronization therapy.

Authors:  Mehmet Uğurlu; Onur Kaypakli; Durmuş Yıldıray Şahin; Yahya Kemal Içen; İbrahim Halil Kurt; Mevlüt Koç
Journal:  J Interv Card Electrophysiol       Date:  2018-05-26       Impact factor: 1.900

8.  Long-term monitoring of respiratory rate in patients with heart failure: the Multiparametric Heart Failure Evaluation in Implantable Cardioverter-Defibrillator Patients (MULTITUDE-HF) study.

Authors:  Giovanni B Forleo; Luca Santini; Massimiliano Campoli; Mario Malavasi; Alberto Scaccia; Maurizio Menichelli; Umberto Riva; Filippo Lamberti; Giovanni Carreras; Serafino Orazi; Valentina Ribatti; Luigi Di Biase; Mariolina Lovecchio; Andrea Natale; Sergio Valsecchi; Francesco Romeo
Journal:  J Interv Card Electrophysiol       Date:  2015-04-28       Impact factor: 1.900

9.  Effects of smoking in patients treated with cardiac resynchronization therapy.

Authors:  Laura Perrotta; Brunilda Xhaferi; Marco Chiostri; Paolo Pieragnoli; Giuseppe Ricciardi; Luigi Di Biase; Andrea Natale; Ilaria Ricceri; Mazda Biria; Dhanunjay Lakkireddy; Alessandro Valleggi; Michele Emdin; Federica Michelotti; Giosuè Mascioli; Angela Pandozi; Massimo Santini; Luigi Padeletti
Journal:  Intern Emerg Med       Date:  2012-12-19       Impact factor: 3.397

10.  Acute exposure to air pollution triggers atrial fibrillation.

Authors:  Mark S Link; Heike Luttmann-Gibson; Joel Schwartz; Murray A Mittleman; Benjamin Wessler; Diane R Gold; Douglas W Dockery; Francine Laden
Journal:  J Am Coll Cardiol       Date:  2013-06-13       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.